Ascletis announces dosing of the first patient in Phase III clinical trial of ASC40

This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40

Jiangsu Alphamab, 3D Medicines and Glenmark sign license agreement for Envafolimab

Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America

Novartis India posts Q3 FY24 PAT at Rs. 26.57 Cr

Novartis India has reported total income of Rs. 106.50 crores during the period ended December 31, 2023

Astec LifeSciences posts Q3 FY24 consolidated loss at Rs. 24.33 Cr

Astec LifeSciences has reported total income of Rs. 51.70 crores during the period ended December 31, 2023

Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr

For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)

Zydus receives USFDA’s final approval for Gabapentin Tablets, 300 mg and 600 mg

Gabapentin is indicated for the management of Postherpetic Neuraligia

Laurus Labs posts Q3 FY24 consolidated PAT at Rs. 23.14 Cr

Laurus Labs has reported total income of Rs. 1197.35 crores during the period ended December 31, 2023

Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr

Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023

Lupin receives tentative USFDA approval for Rivaroxaban Tablets USP

Cipla posts Q3 FY24 consolidated PAT at Rs. 1,055.90 Cr

Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023